Nant Holdings IP Files Neoepitope Validation Patent, US20260110686A1
Summary
Nant Holdings IP, LLC has published patent application US20260110686A1, covering systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor. The application names inventors Kayvan Niazi and Nicholas J. Witchey, was filed on 2025-10-21 under Application No. 19364620, and was published on April 23, 2026. CPC classifications span immunology, peptides, and diagnostics (G01N, C07K, A61K series).
“Systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor are disclosed.”
About this source
USPTO classification C07K covers peptides: short amino-acid chains that form the backbone of antibodies, hormones, vaccines, and increasingly a wider class of therapeutic modalities. Every newly published application in C07K lands in this feed, around 175 a month. Applications publish 18 months after filing, so this feed reveals what antibody engineering groups, vaccine developers, and plant biotech researchers were working on in the prior year and a half. Watch this if you compete in biologics, file freedom-to-operate analyses on antibody drug candidates, scout acquisition targets in vaccine platforms, or track protein-based agricultural biotech filings.
What changed
Nant Holdings IP, LLC has published patent application US20260110686A1 for validation of neoepitope presentation. The application covers systems and methods that use sequence information to predict MHC presentation of a tumor neoepitope and to predict an immune response against that neoepitope. The filing date is October 21, 2025, and the application was published April 23, 2026.
Pharmaceutical and biotechnology companies engaged in cancer immunotherapy development should monitor the prosecution of this application. While the patent has not yet been granted, publication establishes the priority date and makes the technical disclosure publicly available for competitive intelligence and freedom-to-operate analysis.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Validation of Neoepitope Presentation
Application US20260110686A1 Kind: A1 Apr 23, 2026
Assignee
Nant Holdings IP, LLC
Inventors
Kayvan Niazi, Nicholas J. Witchey
Abstract
Systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor are disclosed. The methods use sequence information of the neoepitope.
CPC Classifications
G01N 33/56977 A61K 39/00 A61K 40/11 A61K 40/31 A61K 40/4201 C07K 14/47 C07K 14/7051 C07K 16/30 G01N 33/5758 G01N 2333/70539
Filing Date
2025-10-21
Application No.
19364620
Mentioned entities
Parties
Related changes
Get daily alerts for USPTO Patent Applications - Peptides (C07K)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Peptides (C07K) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.